NCT04442425
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Enrolling by invitation
Drug Category: Other
Key Eligibility Criteria:
Gender: All
Age: 12 Years and older (Child, Adult, Older Adult))
Location of Metastases:
Additional Notes:
Exclusions: Patients with symptomatic, unstable, untreated brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT04442425